[Skip to Content]
[Skip to Content Landing]

Management of Trigeminal Autonomic Cephalalgias Including Chronic ClusterA Review

To identify the key insights or developments described in this article
1 Credit CME
Abstract

Importance  Trigeminal autonomic cephalalgias (TACs) comprise a unique collection of primary headache disorders characterized by moderate or severe unilateral pain, localized in in the area of distribution of the first branch of the trigeminal nerve, accompanied by cranial autonomic symptoms and signs. Most TACs are rare diseases, which hampers the possibility of performing randomized clinical trials and large studies. Therefore, knowledge of treatment efficacy must be based only on observational studies, rare disease registries, and case reports, where real-world data and evidence play an important role in health care decisions.

Observations  Chronic cluster headache is the most common of these disorders, and the literature offers some evidence from randomized clinical trials to support the use of pharmacologic and neurostimulation treatments. Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, was not effective at 3 months in a randomized clinical trial but showed efficacy at 12 months in a large case series. For the other TACs (ie, paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms), only case reports and case series are available to guide physicians in everyday management.

Conclusions and Relevance  The accumulation of epidemiologic, pathophysiologic, natural history knowledge, and data from case series and small controlled trials, especially over the past 20 years from investigators around the world, has added to the previously limited evidence and has helped advance and inform the treatment approach to rare TACs, which can be extremely challenging for clinicians.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: November 3, 2022.

Published Online: January 17, 2023. doi:10.1001/jamaneurol.2022.4804

Corresponding Author: Hans Christoph Diener, MD, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Department of Neuroepidemiology, University Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany (hans.diener@uk-essen.de).

Conflict of Interest Disclosures: Dr Diener reported personal fees from Eli Lilly and Company, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; other support from WebMD as author; grants from the German Research Council, German Ministry of Education and Research, and the European Union during the conduct of the study; serves on the editorial board of Cephalalgia, Lancet Neurology, and Drugs; and is a member of the clinical trials committee of the International Headache Society. Dr Tassorelli reported personal fees from AbbVie, Eli Lilly and Company, Novartis, Teva Pharmaceuticals, Lundbeck, Dompé, and WebMD; grants from AbbVie during the conduct of the study; is principal investigator or collaborator in clinical trials sponsored by Alder, Eli Lilly and Company, IBSA, Novartis, and Teva Pharmaceuticals; grants from the European Commission, the Italian Ministry of Health, the Italian Ministry of University, and the Migraine Research Foundation; is president of and serves on the clinical trials committee for the International Headache Society; and serves on the editorial boards of Cephalalgia and The Journal of Headache and Pain. Dr Dodick reported personal fees from AbbVie, Acorda, AEON, Alcobra, Alder, Allergan, American Academy of Neurology, Amgen, Arteaus, Atria Health, Autonomic Technologies, Axsome, Biocentric, Biohaven, Boston Scientific, Bristol Myers Squibb, CapiThera, CC Ford West Group, Cerecin, Ceruvia, Charleston Laboratories, Colucid, CoolTech Medical, CTRLM, Decision Resources, Dr Reddy’s–Promius Pharma, electroCore, Eli Lilly and Company, eNeura, Equinox, Ethicon, Foresight, Genentech, GSK, Impax, Impel, Insys, IntraMed, Ispen, Labrys, Linpharma, Lundbeck, Magellan, MAP BioPharma, Medtronic, Merck, Neurolief, Nocira, Novartis, NuPathe, Oxford University Press, Perfood, Pfizer, Pieris, Praxis, Revance, SAGE Publishing, Salvia, Satsuma, St Jude, Supernus, Teva Pharmaceuticals, Theranica, Tonix, UpToDate, Vedanta, Wiley Blackwell, WL Gore, Wolters Kluwer Health, Xenon, Xoc Pharmaceuticals, Zogenix, Zosano, and ZP Opco; grants and personal fees from Cefaly, electroCore, Eli Lilly and Company, Novartis, Merz Pharma, Teva Pharmaceuticals, Specifar, Amgen, Biogen, and Genesis Pharma; personal fees and nonfinancial support from West Virginia University Foundation, Canadian Headache Society, Healthlogix, Universal Meeting Management, WebMD/Medscape, Oregon Health Science Center, Albert Einstein University, University of Toronto, Synergy, MedNet, Peer View Institute for Medical Education, Medicom, Medlogix, Chameleon Communications, Academy for Continued Healthcare Learning, Haymarket Medical Education, Global Scientific Communications, Miller Medical, MeetingLogiX, University of British Columbia, University of Southern California, University of California (Los Angeles), American Academy of Neurology, and Canadian Headache Society outside the submitted work; nonfinancial support from Starr Clinical, International Headache Society, American Headache Society, American Brain Foundation, and American Migraine Foundation; a patent for Wolters Kluwer with royalties paid, for Oxford University Press with royalties paid, Cambridge University Press with royalties paid, for botulinum toxin dosage regimen for chronic migraine prophylaxis (nonroyalty bearing) issued, and for Synaquell (Precon Health) pending; research support from Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, and Patient-Centered Outcomes Research Institute; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from American Migraine Foundation, American Brain Foundation, International Headache Society Global Patient Advocacy Coalition; stock options/shareholder/patents/board of directors from Aural Analytics, Axon Therapeutics, ExSano, Man and Science, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, King-Devick Technologies, Precon Health, AYYA Biosciences, and Atria Health; payment or honoraria for lectures, presentations, and educational events from Amgen, Novartis, Eli Lilly and Company, Teva Pharmaceuticals, Allergan, AbbVie, Lundbeck, Biohaven, and Pfizer; and honoraria from Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, and WebMD Health/Medscape.

References
1.
Hoffmann  J , May  A .  Diagnosis, pathophysiology, and management of cluster headache.   Lancet Neurol. 2018;17(1):75-83. doi:10.1016/S1474-4422(17)30405-2PubMedGoogle ScholarCrossref
2.
Diener  HC , May  A .  Drug treatment of cluster headache.   Drugs. 2022;82(1):33-42. doi:10.1007/s40265-021-01658-zPubMedGoogle ScholarCrossref
3.
Burish  MJ , Rozen  TD .  Trigeminal autonomic cephalalgias.   Neurol Clin. 2019;37(4):847-869. doi:10.1016/j.ncl.2019.07.001PubMedGoogle ScholarCrossref
4.
Schindler  EAD , Burish  MJ .  Recent advances in the diagnosis and management of cluster headache.   BMJ. 2022;376:e059577. doi:10.1136/bmj-2020-059577PubMedGoogle ScholarCrossref
5.
de Coo  IF , Marin  JC , Silberstein  SD ,  et al.  Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a meta-analysis.   Cephalalgia. 2019;39(8):967-977. doi:10.1177/0333102419856607PubMedGoogle ScholarCrossref
6.
Dodick  DW , Goadsby  PJ , Lucas  C ,  et al.  Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment.   Cephalalgia. 2020;40(9):935-948. doi:10.1177/0333102420905321PubMedGoogle ScholarCrossref
7.
Goadsby  PJ , Dodick  DW , Leone  M ,  et al.  Trial of galcanezumab in prevention of episodic cluster headache.   N Engl J Med. 2019;381(2):132-141. doi:10.1056/NEJMoa1813440PubMedGoogle ScholarCrossref
8.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.  Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
9.
Giani  L , Proietti Cecchini  A , Leone  M .  Cluster headache and risk of chronic transformation.   Neurol Sci. 2020;41(suppl 2):497-498. doi:10.1007/s10072-020-04674-1Google ScholarCrossref
10.
Fischera  M , Marziniak  M , Gralow  I , Evers  S .  The incidence and prevalence of cluster headache: a meta-analysis of population-based studies.   Cephalalgia. 2008;28(6):614-618. doi:10.1111/j.1468-2982.2008.01592.xPubMedGoogle ScholarCrossref
11.
Cohen  AS , Mathura  MS , Burns  B , Goadsby  PJ .  Randomized, double-blind placebo-controlled trial of high-flow inhaled oxygen in acute cluster headache.   Cephalalgia. 2007;27:1188.Google ScholarCrossref
12.
Law  S , Derry  S , Moore  RA .  Triptans for acute cluster headache.   Cochrane Database Syst Rev. 2013;2013(7):CD008042. doi:10.1002/14651858.CD008042.pub3PubMedGoogle ScholarCrossref
13.
Dodick  D , Lipton  RB , Martin  V ,  et al; Triptan Cardiovascular Safety Expert Panel.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.   Headache. 2004;44(5):414-425. doi:10.1111/j.1526-4610.2004.04078.xPubMedGoogle ScholarCrossref
14.
van Vliet  JA , Bahra  A , Martin  V ,  et al.  Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study.   Neurology. 2003;60(4):630-633. doi:10.1212/01.WNL.0000046589.45855.30PubMedGoogle ScholarCrossref
15.
Cohen  AS , Burns  B , Goadsby  PJ .  High-flow oxygen for treatment of cluster headache: a randomized trial.   JAMA. 2009;302(22):2451-2457. doi:10.1001/jama.2009.1855PubMedGoogle ScholarCrossref
16.
Dirkx  THT , Haane  DYP , Koehler  PJ .  Oxygen treatment for cluster headache attacks at different flow rates: a double-blind, randomized, crossover study.   J Headache Pain. 2018;19(1):94. doi:10.1186/s10194-018-0917-4PubMedGoogle ScholarCrossref
17.
Ekbom  K , Monstad  I , Prusinski  A , Cole  JA , Pilgrim  AJ , Noronha  D ; The Sumatriptan Cluster Headache Study Group.  Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study.   Acta Neurol Scand. 1993;88(1):63-69. doi:10.1111/j.1600-0404.1993.tb04189.xPubMedGoogle ScholarCrossref
18.
Hardebo  JE , Dahlöf  C .  Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache.   Cephalalgia. 1998;18(7):487-489. doi:10.1046/j.1468-2982.1998.1807487.xPubMedGoogle ScholarCrossref
19.
Schuh-Hofer  S , Reuter  U , Kinze  S , Einhäupl  KM , Arnold  G .  Treatment of acute cluster headache with 20 mg sumatriptan nasal spray: an open pilot study.   J Neurol. 2002;249(1):94-99. doi:10.1007/PL00007854PubMedGoogle ScholarCrossref
20.
Cittadini  E , May  A , Straube  A , Evers  S , Bussone  G , Goadsby  PJ .  Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study.   Arch Neurol. 2006;63(11):1537-1542. doi:10.1001/archneur.63.11.nct60002PubMedGoogle ScholarCrossref
21.
Rapoport  AM , Mathew  NT , Silberstein  SD ,  et al.  Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study.   Neurology. 2007;69(9):821-826. doi:10.1212/01.wnl.0000267886.85210.37PubMedGoogle ScholarCrossref
22.
Hedlund  C , Rapoport  AM , Dodick  DW , Goadsby  PJ .  Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies.   Headache. 2009;49(9):1315-1323. doi:10.1111/j.1526-4610.2009.01518.xPubMedGoogle ScholarCrossref
23.
Silberstein  SD , Mechtler  LL , Kudrow  DB ,  et al; ACT1 Study Group.  Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study.   Headache. 2016;56(8):1317-1332. doi:10.1111/head.12896PubMedGoogle ScholarCrossref
24.
Goadsby  PJ , de Coo  IF , Silver  N ,  et al; ACT2 Study Group.  Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study.   Cephalalgia. 2018;38(5):959-969. doi:10.1177/0333102417744362PubMedGoogle ScholarCrossref
25.
Schoenen  J , Jensen  RH , Lantéri-Minet  M ,  et al.  Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment: pathway CH-1: a randomized, sham-controlled study.   Cephalalgia. 2013;33(10):816-830. doi:10.1177/0333102412473667PubMedGoogle ScholarCrossref
26.
Goadsby  PJ , Sahai-Srivastava  S , Kezirian  EJ ,  et al.  Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial.   Lancet Neurol. 2019;18(12):1081-1090. doi:10.1016/S1474-4422(19)30322-9PubMedGoogle ScholarCrossref
27.
Ansarinia  M , Rezai  A , Tepper  SJ ,  et al.  Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches.   Headache. 2010;50(7):1164-1174. doi:10.1111/j.1526-4610.2010.01661.xPubMedGoogle ScholarCrossref
28.
Jürgens  TP , Barloese  M , May  A ,  et al.  Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache.   Cephalalgia. 2017;37(5):423-434. doi:10.1177/0333102416649092PubMedGoogle ScholarCrossref
29.
Barloese  M , Petersen  A , Stude  P , Jürgens  T , Jensen  RH , May  A .  Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry.   J Headache Pain. 2018;19(1):6. doi:10.1186/s10194-017-0828-9PubMedGoogle ScholarCrossref
30.
Jürgens  TP , Schoenen  J , Rostgaard  J ,  et al.  Stimulation of the sphenopalatine ganglion in intractable cluster headache: expert consensus on patient selection and standards of care.   Cephalalgia. 2014;34(13):1100-1110. doi:10.1177/0333102414530524PubMedGoogle ScholarCrossref
31.
May  A .  The need for continued care after sponsor closure.   Lancet Neurol. 2020;19(3):205. doi:10.1016/S1474-4422(20)30023-5PubMedGoogle ScholarCrossref
32.
Gabai  IJ , Spierings  EL .  Prophylactic treatment of cluster headache with verapamil.   Headache. 1989;29(3):167-168. doi:10.1111/j.1526-4610.1989.hed2903167.xPubMedGoogle ScholarCrossref
33.
Blau  JN , Engel  HO .  Individualizing treatment with verapamil for cluster headache patients.   Headache. 2004;44(10):1013-1018. doi:10.1111/j.1526-4610.2004.04196.xPubMedGoogle ScholarCrossref
34.
Petersen  AS , Lund  N , Jensen  RH , Barloese  M .  Real-life treatment of cluster headache in a tertiary headache center: results from the Danish Cluster Headache Survey.   Cephalalgia. 2021;41(5):525-534. doi:10.1177/0333102420970455PubMedGoogle ScholarCrossref
35.
Ekbom  K .  Treatment of cluster headache: clinical trials, design and results.   Cephalalgia. 1995;15(suppl 15):33-36.PubMedGoogle ScholarCrossref
36.
Mathew  NT , Kailasam  J , Meadors  L .  Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.   Headache. 2002;42(8):796-803. doi:10.1046/j.1526-4610.2002.02183.xPubMedGoogle ScholarCrossref
37.
Láinez  MJ , Pascual  J , Pascual  AM , Santonja  JM , Ponz  A , Salvador  A .  Topiramate in the prophylactic treatment of cluster headache.   Headache. 2003;43(7):784-789. doi:10.1046/j.1526-4610.2003.03137.xPubMedGoogle ScholarCrossref
38.
Leone  M , Dodick  D , Rigamonti  A ,  et al.  Topiramate in cluster headache prophylaxis: an open trial.   Cephalalgia. 2003;23(10):1001-1002. doi:10.1046/j.1468-2982.2003.00665.xPubMedGoogle ScholarCrossref
39.
Huang  WY , Lo  MC , Wang  SJ , Tsai  JJ , Wu  HM .  Topiramate in prevention of cluster headache in the Taiwanese.   Neurol India. 2010;58(2):284-287. doi:10.4103/0028-3886.63784PubMedGoogle ScholarCrossref
40.
Leandri  M , Luzzani  M , Cruccu  G , Gottlieb  A .  Drug-resistant cluster headache responding to gabapentin: a pilot study.   Cephalalgia. 2001;21(7):744-746. doi:10.1046/j.1468-2982.2001.00260.xPubMedGoogle ScholarCrossref
41.
Schuh-Hofer  S , Israel  H , Neeb  L , Reuter  U , Arnold  G .  The use of gabapentin in chronic cluster headache patients refractory to first-line therapy.   Eur J Neurol. 2007;14(6):694-696. doi:10.1111/j.1468-1331.2007.01738.xPubMedGoogle ScholarCrossref
42.
Leone  M , D’Amico  D , Moschiano  F , Fraschini  F , Bussone  G .  Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups.   Cephalalgia. 1996;16(7):494-496. doi:10.1046/j.1468-2982.1996.1607494.xPubMedGoogle ScholarCrossref
43.
Pringsheim  T , Magnoux  E , Dobson  CF , Hamel  E , Aubé  M .  Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study.   Headache. 2002;42(8):787-792. doi:10.1046/j.1526-4610.2002.02181.xPubMedGoogle ScholarCrossref
44.
Riesenberg  R , Gaul  C , Stroud  CE ,  et al.  Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.   Cephalalgia. 2022;42(11-12):1225-1235. doi:10.1177/03331024221103509PubMedGoogle ScholarCrossref
45.
Wilbrink  LA , de Coo  IF , Doesborg  PGG ,  et al; ICON study group.  Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.   Lancet Neurol. 2021;20(7):515-525. doi:10.1016/S1474-4422(21)00101-0PubMedGoogle ScholarCrossref
46.
Aibar-Durán  JA , Álvarez Holzapfel  MJ , Rodríguez  R , Belvis Nieto  R , Roig Arnall  C , Molet Teixido  J .  Occipital nerve stimulation and deep brain stimulation for refractory cluster headache: a prospective analysis of efficacy over time.   J Neurosurg. Published online January 17, 2020. doi:10.3171/2019.11.JNS192042PubMedGoogle ScholarCrossref
47.
Miller  S , Watkins  L , Matharu  M .  Treatment of intractable chronic cluster headache by occipital nerve stimulation: a cohort of 51 patients.   Eur J Neurol. 2017;24(2):381-390. doi:10.1111/ene.13215PubMedGoogle ScholarCrossref
48.
Leplus  A , Fontaine  D , Donnet  A ,  et al; French ONS registry group.  Long-term efficacy of occipital nerve stimulation for medically intractable cluster headache.   Neurosurgery. 2021;88(2):375-383. doi:10.1093/neuros/nyaa373PubMedGoogle ScholarCrossref
49.
Fontaine  D , Christophe Sol  J , Raoul  S ,  et al.  Treatment of refractory chronic cluster headache by chronic occipital nerve stimulation.   Cephalalgia. 2011;31(10):1101-1105. doi:10.1177/0333102411412086PubMedGoogle ScholarCrossref
50.
Xin  B , Xie  K , Luo  G , Yao  M .  Long-term follow-up safety and effectiveness of CT-guided radiofrequency thermocoagulation of sphenopalatine ganglion in refractory headache treatment.   Pain Ther. 2022;11(3):1011-1023. doi:10.1007/s40122-022-00401-0PubMedGoogle ScholarCrossref
51.
Gaul  C , Diener  HC , Silver  N ,  et al; PREVA Study Group.  Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study.   Cephalalgia. 2016;36(6):534-546. doi:10.1177/0333102415607070PubMedGoogle ScholarCrossref
52.
Medrea  I , Christie  S , Tepper  SJ , Thavorn  K , Hutton  B .  Effects of acute and preventive therapies for episodic and chronic cluster headache: a scoping review of the literature.   Headache. 2022;62(3):329-362. doi:10.1111/head.14284PubMedGoogle ScholarCrossref
53.
Pompilio  G , Migliore  A , Integlia  D .  Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs.   Eur Rev Med Pharmacol Sci. 2021;25(3):1631-1640. doi:10.26355/eurrev_202102_24874PubMedGoogle Scholar
54.
Steiner  TJ , Hering  R , Couturier  EG , Davies  PT , Whitmarsh  TE .  Double-blind placebo-controlled trial of lithium in episodic cluster headache.   Cephalalgia. 1997;17(6):673-675. doi:10.1046/j.1468-2982.1997.1706673.xPubMedGoogle ScholarCrossref
55.
Goadsby  PJ , Edvinsson  L .  Human in vivo evidence for trigeminovascular activation in cluster headache: neuropeptide changes and effects of acute attacks therapies.   Brain. 1994;117(Pt 3):427-434. doi:10.1093/brain/117.3.427PubMedGoogle ScholarCrossref
56.
Láinez  MJA , Schoenen  J , Stroud  C ,  et al.  Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.   Headache. 2022;62(1):65-77. doi:10.1111/head.14234PubMedGoogle ScholarCrossref
57.
Vukovic Cvetkovic  V , Jensen  RH .  Neurostimulation for the treatment of chronic migraine and cluster headache.   Acta Neurol Scand. 2019;139(1):4-17. doi:10.1111/ane.13034PubMedGoogle ScholarCrossref
58.
Magis  D , Gerardy  PY , Remacle  JM , Schoenen  J .  Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache.   Headache. 2011;51(8):1191-1201. doi:10.1111/j.1526-4610.2011.01973.xPubMedGoogle ScholarCrossref
59.
Mueller  O , Diener  HC , Dammann  P ,  et al.  Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications.   Cephalalgia. 2013;33(16):1283-1291. doi:10.1177/0333102413493193PubMedGoogle ScholarCrossref
60.
Franzini  A , Clerici  E , Navarria  P , Picozzi  P .  Gamma knife radiosurgery for the treatment of cluster headache: a systematic review.   Neurosurg Rev. 2022;45(3):1923-1931. doi:10.1007/s10143-021-01725-9PubMedGoogle ScholarCrossref
61.
Leone  M .  Deep brain stimulation in headache.   Lancet Neurol. 2006;5(10):873-877. doi:10.1016/S1474-4422(06)70575-0PubMedGoogle ScholarCrossref
62.
Coppola  G , Magis  D , Casillo  F ,  et al.  Neuromodulation for chronic daily headache.   Curr Pain Headache Rep. 2022;26(3):267-278. doi:10.1007/s11916-022-01025-xPubMedGoogle ScholarCrossref
63.
Dodick  DW , Goadsby  PJ , Ashina  M ,  et al.  Challenges and complexities in designing cluster headache prevention clinical trials: a narrative review.   Headache. 2022;62(4):453-472. doi:10.1111/head.14292PubMedGoogle ScholarCrossref
64.
Barloese  MCJ , Beske  RP , Petersen  AS , Haddock  B , Lund  N , Jensen  RH .  Episodic and chronic cluster headache: differences in family history, traumatic head injury, and chronorisk.   Headache. 2020;60(3):515-525. doi:10.1111/head.13730PubMedGoogle ScholarCrossref
65.
Moisset  X , Giraud  P , Meunier  E ,  et al.  Ketamine-magnesium for refractory chronic cluster headache: a case series.   Headache. 2020;60(10):2537-2543. doi:10.1111/head.14005PubMedGoogle ScholarCrossref
66.
Lampl  C , Rudolph  M , Bräutigam  E .  OnabotulinumtoxinA in the treatment of refractory chronic cluster headache.   J Headache Pain. 2018;19(1):45. doi:10.1186/s10194-018-0874-yPubMedGoogle ScholarCrossref
67.
Degirmenci  Y , Kececi  H .  Can paroxysmal hemicrania be bilateral? a case report.   Neurol Sci. 2016;37(8):1377-1378. doi:10.1007/s10072-016-2560-7PubMedGoogle ScholarCrossref
68.
Pareja  JA , Caminero  AB , Franco  E , Casado  JL , Pascual  J , Sánchez del Río  M .  Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.   Cephalalgia. 2001;21(9):906-910. doi:10.1046/j.1468-2982.2001.00287.xPubMedGoogle ScholarCrossref
69.
Cittadini  E , Matharu  MS , Goadsby  PJ .  Paroxysmal hemicrania: a prospective clinical study of 31 cases.   Brain. 2008;131(pt 4):1142-1155. doi:10.1093/brain/awn010PubMedGoogle ScholarCrossref
70.
Prakash  S , Belani  P , Susvirkar  A , Trivedi  A , Ahuja  S , Patel  A .  Paroxysmal hemicrania: a retrospective study of a consecutive series of 22 patients and a critical analysis of the diagnostic criteria.   J Headache Pain. 2013;14(1):26. doi:10.1186/1129-2377-14-26PubMedGoogle ScholarCrossref
71.
Boes  CJ , Dodick  DW .  Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients.   Headache. 2002;42(8):699-708. doi:10.1046/j.1526-4610.2002.02171.xPubMedGoogle ScholarCrossref
72.
Mauritz  MD , Enninger  A , Wamsler  C , Wager  J , Zernikow  B .  Long-term outcome of indomethacin treatment in pediatric patients with paroxysmal hemicrania: a case series.   Children (Basel). 2021;8(2):101. doi:10.3390/children8020101PubMedGoogle ScholarCrossref
73.
Baraldi  C , Pellesi  L , Guerzoni  S , Cainazzo  MM , Pini  LA .  Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.   J Headache Pain. 2017;18(1):71. doi:10.1186/s10194-017-0777-3PubMedGoogle ScholarCrossref
74.
Kamourieh  S , Lagrata  S , Matharu  MS .  Non-invasive vagus nerve stimulation is beneficial in chronic paroxysmal hemicrania.   J Neurol Neurosurg Psychiatry. 2019;90(9):1072-1074. doi:10.1136/jnnp-2018-319538PubMedGoogle ScholarCrossref
75.
Tso  AR , Marin  J , Goadsby  PJ .  Noninvasive vagus nerve stimulation for treatment of indomethacin-sensitive headaches.   JAMA Neurol. 2017;74(10):1266-1267. doi:10.1001/jamaneurol.2017.2122PubMedGoogle ScholarCrossref
76.
Prakash  S , Patel  P .  Hemicrania continua: clinical review, diagnosis and management.   J Pain Res. 2017;10:1493-1509. doi:10.2147/JPR.S128472PubMedGoogle ScholarCrossref
77.
Rozen  TD .  How effective is melatonin as a preventive treatment for hemicrania continua? a clinic-based study.   Headache. 2015;55(3):430-436. doi:10.1111/head.12489PubMedGoogle ScholarCrossref
78.
Miller  S , Correia  F , Lagrata  S , Matharu  MS .  OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients.   J Headache Pain. 2015;16:19. doi:10.1186/s10194-015-0502-zPubMedGoogle ScholarCrossref
79.
Trimboli  M , Al-Kaisy  A , Andreou  AP , Murphy  M , Lambru  G .  Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: a real-world experience.   Cephalalgia. 2017;333102417731349. doi:10.1177/0333102417731349PubMedGoogle ScholarCrossref
80.
Marmura  MJ .  Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias.   Curr Pain Headache Rep. 2010;14(2):145-150. doi:10.1007/s11916-010-0098-6PubMedGoogle ScholarCrossref
81.
Lambru  G , Stubberud  A , Rantell  K , Lagrata  S , Tronvik  E , Matharu  MS .  Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis.   J Neurol Neurosurg Psychiatry. 2021;92(3):233-241. doi:10.1136/jnnp-2020-323999PubMedGoogle ScholarCrossref
82.
Weng  HY , Cohen  AS , Schankin  C , Goadsby  PJ .  Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial.   Cephalalgia. 2018;38(9):1554-1563. doi:10.1177/0333102417739304PubMedGoogle ScholarCrossref
83.
Miller  S , Akram  H , Lagrata  S , Hariz  M , Zrinzo  L , Matharu  M .  Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks.   Brain. 2016;139(Pt 10):2631-2640. doi:10.1093/brain/aww204PubMedGoogle ScholarCrossref
84.
Miller  S , Watkins  L , Matharu  M .  Long-term follow up of intractable chronic short lasting unilateral neuralgiform headache disorders treated with occipital nerve stimulation.   Cephalalgia. 2018;38(5):933-942. doi:10.1177/0333102417721716PubMedGoogle ScholarCrossref
85.
Lambru  G , Lagrata  S , Levy  A ,  et al.  Trigeminal microvascular decompression for short-lasting unilateral neuralgiform headache attacks.   Brain. 2022;145(8):2882-2893. doi:10.1093/brain/awac109PubMedGoogle ScholarCrossref
86.
Miller  S , Lagrata  S , Watkins  L , Matharu  M .  Occipital nerve stimulation for medically refractory chronic paroxysmal hemicrania.   Headache. 2017;57(10):1610-1613. doi:10.1111/head.13187PubMedGoogle ScholarCrossref
87.
Cittadini  E , Goadsby  PJ .  Hemicrania continua: a clinical study of 39 patients with diagnostic implications.   Brain. 2010;133(Pt 7):1973-1986. doi:10.1093/brain/awq137PubMedGoogle ScholarCrossref
88.
Mehta  A , Chilakamarri  P , Zubair  A , Kuruvilla  DE .  Hemicrania continua: a clinical perspective on diagnosis and management.   Curr Neurol Neurosci Rep. 2018;18(12):95. doi:10.1007/s11910-018-0899-2PubMedGoogle ScholarCrossref
89.
Prakash  S , Golwala  P .  A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients.   Cephalalgia. 2012;32(11):860-868. doi:10.1177/0333102412452043PubMedGoogle ScholarCrossref
90.
Prakash  S , Shah  ND .  Delayed response of indomethacin in patients with hemicrania continua: real or phantom headache?   Cephalalgia. 2010;30(3):375-379. doi:10.1111/j.1468-2982.2009.01910.xPubMedGoogle ScholarCrossref
91.
Summ  O , Andreou  AP , Akerman  S , Holland  PR , Hoffmann  J , Goadsby  PJ .  Differential actions of indomethacin: clinical relevance in headache.   Pain. 2021;162(2):591-599. doi:10.1097/j.pain.0000000000002032PubMedGoogle ScholarCrossref
92.
Fantini  J , Koscica  N , Zorzon  M , Belluzzo  M , Granato  A .  Hemicrania continua with visual aura successfully treated with a combination of indomethacin and topiramate.   Neurol Sci. 2015;36(4):643-644. doi:10.1007/s10072-014-2036-6PubMedGoogle ScholarCrossref
93.
Prakash  S , Rana  K .  Topiramate as an indomethacin-sparing agent in hemicrania continua: a report of 2 cases.   Headache. 2019;59(3):444-445. doi:10.1111/head.13490PubMedGoogle ScholarCrossref
94.
Guerrero  AL , Herrero-Velázquez  S , Peñas  ML ,  et al.  Peripheral nerve blocks: a therapeutic alternative for hemicrania continua.   Cephalalgia. 2012;32(6):505-508. doi:10.1177/0333102412439800PubMedGoogle ScholarCrossref
95.
Miller  S , Watkins  L , Matharu  MS .  Treatment of intractable hemicrania continua by occipital nerve stimulation.   J Neurol Neurosurg Psychiatry. 2017;88(9):805-806. doi:10.1136/jnnp-2017-315747PubMedGoogle ScholarCrossref
96.
Burns  B , Watkins  L , Goadsby  PJ .  Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study.   Lancet Neurol. 2008;7(11):1001-1012. doi:10.1016/S1474-4422(08)70217-5PubMedGoogle ScholarCrossref
97.
Cohen  AS , Matharu  MS , Goadsby  PJ .  Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)--a prospective clinical study of SUNCT and SUNA.   Brain. 2006;129(Pt 10):2746-2760. doi:10.1093/brain/awl202PubMedGoogle ScholarCrossref
98.
Lambru  G , Matharu  MS .  SUNCT, SUNA and trigeminal neuralgia: different disorders or variants of the same disorder?   Curr Opin Neurol. 2014;27(3):325-331. doi:10.1097/WCO.0000000000000090PubMedGoogle ScholarCrossref
99.
Williams  MH , Broadley  SA .  SUNCT and SUNA: clinical features and medical treatment.   J Clin Neurosci. 2008;15(5):526-534. doi:10.1016/j.jocn.2006.09.006PubMedGoogle ScholarCrossref
100.
Yalın  OO , Uludüz  D , Özge  A .  Peripheral nerve blocks for the treatment of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) during pregnancy.   Agri. 2018;30(1):28-30. doi:10.5505/agri.2016.25991PubMedGoogle ScholarCrossref
101.
Hassan  S , Lagrata  S , Levy  A , Matharu  M , Zrinzo  L .  Microvascular decompression or neuromodulation in patients with SUNCT and trigeminal neurovascular conflict?   Cephalalgia. 2018;38(2):393-398. doi:10.1177/0333102417735847PubMedGoogle ScholarCrossref
102.
Ornello  R , Palmisani  S , Murphy  M , Sacco  S , Al-Kaisy  A , Lambru  G .  Sphenopalatine ganglion pulsed radiofrequency for the treatment of refractory chronic SUNCT and SUNA: a prospective case series.   Headache. 2020;60(5):938-945. doi:10.1111/head.13788PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close